Considering that there is no efficiency therapy targets for ER− breast cancer, the present study not only strongly suggested that GPR30 can be considered as a potential important target but also provided G-1 as a drug candidate for ER− breast cancer therapy. This evidence concerns the gene GPER1 and breast cancer.